Skip to main content

Project Bulletin

Project Bulletin, August 3, 2026: Kraków, Poland; Rock Hill, South Carolina; El Paso, Texas

by Alexis Elmore

Kraków will mark the company's second manufacturing facility dedicated to electrified trucks. Photo courtesy of MAN Truck & Bus

AN ELECTRIFIED EXPANSION

Germany-based MAN Truck & Bus is heading back to its manufacturing operations in southern Poland to deliver a $1.3 billion expansion. This initiative follows the company’s MAN2030 future program, which includes a focus on investing in the next generation of vehicles for the European market. At its Kraków production site, the project will introduce a new body-in-white and paint shop, additional production facilities for manufacturing painted truck bodies and an expansion of current cab assembly activities. This move will enable MAN Truck & Bus to double its production area to over 2.9 million sq. ft., making room for the company to also launch new fully electric vehicles. This will establish the Kraków plant as the company’s second electrified truck facility. “With these investments in Poland, we are further expanding our presence in Europe. Kraków has played an important role in our production network for many years,” said MAN Truck & Bus CEO Alexander Vlaskamp. “The expansion into a full-scale manufacturing plant and the start of series production of our electric light-duty truck range position us strongly for the ongoing transformation of the industry and prepare us well for the future.”

Octapharma’s investment will create 1,500 direct new jobs in Rock Hill, South Carolina.
Getty Images

BIOMEDICAL MANUFACTUERER ENTERS U.S. SUPPLY CHAIN

Last week, the world’s largest privately-owned and independent plasma fractionator Octapharma announced a project that will soon become South Carolina’s largest private biomedical investment in state history. The company selected a 50-acre site at the Palmetto Research Park in Rock Hill, where it will invest $1.5 billion to establish its first U.S.-based manufacturing site. Here, Octapharma will introduce its portfolio of plasma-derived therapies, in addition to bleeding management and trauma care products, in order to boost domestic biomedical supply chains. “We expect significant future growth, driven by our existing life-saving therapies and a strong pipeline of new products,” said Octapharma Chairman and CEO Wolfgang Marguerre. “Our manufacturing capacity must evolve to support this ambition, and our U.S. manufacturing facility will be an important milestone. From a U.S. national security perspective, having the ability to produce and supply our therapies domestically is invaluable.” The company stated South Carolina was selected based on its proven advanced manufacturing infrastructure, access to deep-water ports, talent and proximity to major logistics networks.

 Meta will invest $500,000 into STEM education at El Paso public schools, while the BlackRock Foundation will provide up to $30 million for its Texas through Future Builders workforce initiative.
Photo courtesy of Meta

BLACKROCK BACKS META IN TEXAS

Meta Platforms and BlackRock are teaming up to pursue the development of a new $14 billion data center campus in El Paso, Texas. After a highly competitive process, Meta determined BlackRock as its ideal partner for rapid execution. “Building the infrastructure for superintelligence is key to making sure the benefits of this technology are distributed to everyone,” says Meta Founder and CEO Mark Zuckerberg. “Our partnership with Larry and the team at BlackRock allows us to move faster and at greater scale, pairing our deep expertise in designing and operating world-class data centers with one of the world’s leading infrastructure investors.” The future 1-gigawatt data center campus is expected to come online in 2028, creating 300 direct jobs. BlackRock will own an 80% interest in the project, while Meta will retain 20% ownership. Meta plans to enter lease agreements for use of the entire campus with initial four-year terms which have the option to extend.

Reports compiled and written by Alexis Elmore